BackNeurocrine Biosciences Overview
Neurocrine Biosciences, Inc.

Neurocrine Biosciences Target Price

Analysts' 12-month price predictions for NBIX.

Get informed when a big investor buys or sells

+ Follow

Share Price

$161.44

Average Target Price

$214.3332.8% upside

6 analysts in the last 4 months

High: $230 | Low: $195

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-02Goldman SachsCorinne Johnson$21331.9% upsideOpen
2026-05-21BernsteinJeffrey Walch$22136.9% upsideOpen
2026-05-06Oppenheimer$23042.5% upsideOpen
2026-05-06Piper Sandler$20728.2% upsideOpen
2026-04-06Oppenheimer$22036.3% upsideOpen
2026-03-10Cantor FitzgeraldJosh Schimmer$19520.8% upsideOpen
2026-02-23Wolfe Research$1600.9% downsideOpen
2026-02-17Truist FinancialDanielle Brill$14013.3% downsideOpen
2026-02-12Needham$18514.6% upsideOpen
2026-02-12RBC Capital$1779.6% upsideOpen
2026-02-12Wedbush$1516.5% downsideOpen
2026-02-12Morgan Stanley$1737.2% upsideOpen
2026-02-12H.C. Wainwright$19218.9% upsideOpen
2026-01-23UBS$17810.3% upsideOpen
2026-01-08Truist Financial$1694.7% upsideOpen
2026-01-08Morgan Stanley$1758.4% upsideOpen
2026-01-05UBSAshwani Verma$18816.5% upsideOpen
2025-12-17H.C. Wainwright$19822.6% upsideOpen
2025-12-11Stifel Nicolaus$18816.5% upsideOpen
2025-12-08RBC Capital$18011.5% upsideOpen
2025-10-29Truist FinancialDanielle Brill$1726.5% upsideOpen
2025-10-29UBS$18313.4% upsideOpen
2025-10-29RBC Capital$1600.9% downsideOpen
2025-10-29Mizuho Securities$1469.6% downsideOpen
2025-10-29Stifel NicolausPaul Matteis$18313.4% upsideOpen
2025-10-29BMO Capital$1478.9% downsideOpen
2025-10-29NeedhamAmi Fadia$18414% upsideOpen
2025-10-29Piper Sandler$17910.9% upsideOpen
2025-10-29JefferiesAkash Tewari$1747.8% upsideOpen
2025-10-20Morgan Stanley$1684.1% upsideOpen
2025-10-09UBSAshwani Verma$19520.8% upsideOpen
2025-07-31Guggenheim$1758.4% upsideOpen
2025-04-28Canaccord Genuity$1582.1% downsideOpen
2025-04-22H.C. WainwrightAndrew Fein$1684.1% upsideOpen
2025-03-07Morgan Stanley$1507.1% downsideOpen
2025-01-08UBSAshwani Verma$1620.3% upsideOpen
2024-10-31BMO CapitalEvan David Seigerman$12125% downsideOpen
2024-10-22OppenheimerJay Olson$19218.9% upsideOpen
2024-10-10Raymond JamesDanielle Brill$1554% downsideOpen
2024-09-13BMO CapitalEvan David Seigerman$12820.7% downsideOpen
2024-09-09BarclaysCarter Gould$1600.9% downsideOpen
2024-08-29RBC CapitalBrian Abrahams$13615.8% downsideOpen
2024-08-29Piper SandlerDavid Amsellem$1591.5% downsideOpen
2024-07-12Morgan StanleyJeffrey Hung$1705.3% upsideOpen
2024-06-06RBC CapitalBrian Abrahams$14112.7% downsideOpen
2024-05-28UBSAshwani Verma$19319.5% upsideOpen
2024-05-13Evercore ISICory Kasimov$1758.4% upsideOpen
2024-05-02Canaccord GenuitySumant Kulkarni$1641.6% upsideOpen
2024-05-02H.C. WainwrightAndrew Fein$1600.9% downsideOpen
2024-04-23Wells FargoMohit Bansal$1705.3% upsideOpen